NASDAQ:CYTK

Cytokinetics Stock Predictions

Healthcare > Biotechnology

Buy CYTK

*Your capital is at risk

$70.71

-0.200 (-0.282%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

CYTK Prediction Chart

CYTK Predictions History

Latest community submissions for CYTK.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
2poJeff Pro	Feb 7, 2020	$14.52 -0.41%	$14.58	X	99.59%	5
Grayigami @Grayigami.138217	Feb 7, 2020	$14.13 -3.12%	$14.58	X	96.88%	0
GoldenNugget Pro	May 7, 2019	$8.89 -3.90%	$9.25	X	96.10%	0
NameNotImportant Pro	May 2, 2019	$9.11 +7.81%	$8.45	X	92.19%	0
NameNotImportant Pro	May 1, 2019	$8.50 +2.16%	$8.32	X	97.84%	0
NameNotImportant Pro	Apr 23, 2019	$8.08 -9.82%	$8.96	X	90.18%	0
JS Pro	Jan 11, 2018	$9.23 +4.89%	$8.80	X	95.10%	0
JS Pro	Mar 7, 2017	$11.97 +4.09%	$11.50	X	95.90%	0
Blah	Mar 7, 2017	$12.00 +4.35%	$11.50	X	95.70%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CYTK with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CYTOKINETICS

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
RUN $12.83	18.86%	May 06
GLBE $31.61	5.35%	May 05
SAP $172.39	10.69%	May 05
W WCLD $27.34	27.18%	Apr 29
ADBE $243.57	7.61%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by